Bristol-Myers (its new Zelmac partner) is one candidate, with a market cap 20% more than Novartis'.

FORBES: Reviving Novartis

Sandoz chemists discovered Zelmac serendipitously in the late 1980s while looking for chemicals that might improve memory.

FORBES: Reviving Novartis

Novartis is also laying plans for a big TV campaign for Zelmac.

FORBES: Reviving Novartis

The sales force has been training for months to sell Zelmac and will be ready the day it wins approval.

FORBES: Reviving Novartis

But because Novartis' field force is still smaller than Pfizer's or GlaxoSmithKline's, the company has signed on Bristol-Myers Squibb to comarket Zelmac.

FORBES: Reviving Novartis

Later this year Novartis plans to introduce five more drugs to complete the turnaround: Glivec, Zelmac, Xolair and Starlix for diabetes and Zometa for cancer.

FORBES: Reviving Novartis

Zelnorm, formerly known as Zelmac, treats irritable bowel disorder (IBS)--a combination of constipation, stomach pain and other severe symptoms that affects up to 15% of the population, mostly women.

FORBES: Novartis Pushes Ahead On Pipeline Snags

Another is Zelmac, due later this year.

FORBES: Reviving Novartis

Zelmac, a chemical discovered in the 1980s by chemists at what is now Novartis, almost didn't make it to the FDA. Clinical research staff balked at large-scale trials, but the drug caught the eye of Novartis Chief Executive Dan Vasella .

FORBES: Novartis Pushes Ahead On Pipeline Snags